Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier for advanced OPTIONS screeners and volatility tools. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Rigel Pharmaceuticals (RIGL)

Rigel Pharmaceuticals (RIGL)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 350,648
  • Shares Outstanding, K 17,872
  • Annual Sales, $ 179,280 K
  • Annual Income, $ 17,490 K
  • EBIT $ 44 M
  • EBITDA $ 45 M
  • 60-Month Beta 1.34
  • Price/Sales 1.89
  • Price/Cash Flow 17.57
  • Price/Book 18.24

Options Overview Details

View History
  • Implied Volatility 90.48% ( +22.53%)
  • Historical Volatility 48.34%
  • IV Percentile 61%
  • IV Rank 52.35%
  • IV High 166.10% on 06/25/24
  • IV Low 7.41% on 10/11/24
  • Put/Call Vol Ratio 0.11
  • Today's Volume 10
  • Volume Avg (30-Day) 61
  • Put/Call OI Ratio 0.23
  • Today's Open Interest 1,479
  • Open Int (30-Day) 1,276

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 6 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/25
See More
  • Average Estimate 1.42
  • Number of Estimates 4
  • High Estimate 2.78
  • Low Estimate 0.14
  • Prior Year -0.06
  • Growth Rate Est. (year over year) +2,466.67%

Price Performance

See More
Period Period Low Period High Performance
1-Month
16.88 +13.68%
on 05/08/25
25.42 -24.51%
on 05/07/25
-0.22 (-1.13%)
since 04/28/25
3-Month
15.50 +23.81%
on 04/09/25
25.42 -24.51%
on 05/07/25
-3.87 (-16.78%)
since 02/28/25
52-Week
7.48 +156.40%
on 07/05/24
29.82 -35.65%
on 11/12/24
+9.88 (+106.03%)
since 05/28/24

Most Recent Stories

More News
Rigel: Q1 Earnings Snapshot

Rigel: Q1 Earnings Snapshot

RIGL : 19.19 (-2.19%)
4 Healthcare Stocks to Buy as the Sector Faces Government Heat

The U.S. healthcare sector is currently navigating a complex landscape characterized by technological innovation, policy shifts, financial pressures and evolving consumer expectations. While artificial...

FOLD : 6.10 (-2.24%)
RIGL : 19.19 (-2.19%)
ENSG : 146.31 (-0.78%)
BVS : 6.53 (unch)
AXSM Settles Sunosi Patent Litigation With Hikma Pharmaceuticals

Axsome Therapeutics AXSM announced that it has entered into a settlement agreement with Hikma Pharmaceuticals related to patents for its narcolepsy drug, Sunosi (solriamfetol).The settlement agreement...

JAZZ : 107.01 (-2.24%)
RIGL : 19.19 (-2.19%)
ANIP : 57.81 (-0.87%)
AXSM : 102.99 (-0.95%)
ESPR's Q4 Loss Narrower Than Expected, Revenues Increase Y/Y

Esperion Therapeutics ESPR incurred a fourth-quarter 2024 loss of 10 cents per share (excluding one-time expenses of loss on extinguishment of debt and exchange transaction), which was narrower than the...

ESPR : 0.8347 (+1.81%)
RIGL : 19.19 (-2.19%)
PCRX : 25.56 (-1.01%)
Rigel: Q4 Earnings Snapshot

Rigel: Q4 Earnings Snapshot

RIGL : 19.19 (-2.19%)
Retail Investors Bet On Anavex Lifesciences Stock To Outperform Novavax, Rigel Pharma In Q1 On Alzheimer’s Drug Buzz

The intense retail focus on Anavex reflects a broader market interest in neurodegenerative therapies, especially following disappointing trial results from Cassava Sciences’ simufilam.

AVXL : 7.58 (+2.85%)
RIGL : 19.19 (-2.19%)
NVAX : 6.92 (-6.23%)
Small-Cap Stocks Can Outperform Large-Cap Peers in 2025: 5 Top Picks

U.S. stock markets witnessed an impressive rally in 2024 after an astonishing bull run in 2023. Following the 24.2% ascent in 2023, the S&P 500 rallied 23.3% last year. The Dow and the Nasdaq Composite...

LIND : 10.56 (-1.40%)
TZOO : 13.41 (+3.00%)
RIGL : 19.19 (-2.19%)
GHM : 39.78 (-2.43%)
EVER : 23.26 (-0.60%)
Buy 5 Genomics & Synthetic Biology Stocks Likely to Soar in Short Term

Genomics companies analyze and interpret genetic information to uncover insights about genetic variations and disease mechanisms and develop tests, therapies and technologies to advance personalized medicine. Companies...

IMCR : 31.49 (-1.72%)
CRSP : 37.22 (-0.92%)
GLUE : 4.06 (+1.75%)
CSTL : 16.23 (+2.72%)
RIGL : 19.19 (-2.19%)
3 Ways to Invest in Small-Cap Stocks Now

With small-cap stocks surging in response to Donald Trump's re-election and the Federal Reserve's rate cut, investors can tap into this momentum through three distinct ETFs: VBK, DWAS, and UWM, each offering...

TRGP : 159.34 (-1.31%)
LMB : 125.50 (-6.90%)
MOD : 90.81 (-1.77%)
DRS : 42.33 (-0.40%)
DWAS : 81.23 (-1.02%)
AXON : 751.00 (+0.66%)
UWM : 34.23 (-2.14%)
LII : 568.24 (-1.90%)
DECK : 104.32 (-4.26%)
RIGL : 19.19 (-2.19%)
STRL : 187.93 (-1.82%)
VBK : 264.14 (-0.96%)
Rigel: Q3 Earnings Snapshot

Rigel: Q3 Earnings Snapshot

RIGL : 19.19 (-2.19%)

Business Summary

Rigel Pharmaceuticals, Inc. is a clinical-stage drug development company that discovers and develops novel, small-molecule drugs for the treatment of inflammatory diseases, cancer and viral diseases. Its goal is to file one new investigative new drug application in a significant indication each year....

See More

Key Turning Points

3rd Resistance Point 20.31
2nd Resistance Point 20.06
1st Resistance Point 19.62
Last Price 19.19
1st Support Level 18.93
2nd Support Level 18.68
3rd Support Level 18.24

See More

52-Week High 29.82
Fibonacci 61.8% 21.29
Last Price 19.19
Fibonacci 50% 18.65
Fibonacci 38.2% 16.02
52-Week Low 7.48

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
OSZAR »